AB 423
Alternative Names: AB-423Latest Information Update: 09 Mar 2023
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
- Developer Arbutus Biopharma
- Class Antivirals; Bacteriophages; Small molecules
- Mechanism of Action Capsid protein inhibitors; Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics
- 28 Feb 2020 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Canada (PO)